WVP
CNTX icon

Worth Venture Partners’s Context Therapeutics CNTX Stock Holding History

Worth Venture Partners’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-281,889
Closed -$186K – 197
2022
Q4 		$186K Sell
281,889
-40,739
-13% -$43.9K 0.11% 114
2022
Q3 		$358K Buy
322,628
+25,016
+8% +$45K 0.22% 88
2022
Q2 		$565K Sell
297,612
-20,117
-6% -$37.7K 0.33% 74
2022
Q1 		$689K Buy
317,729
+142,762
+82% +$300K 0.32% 74
2021
Q4 		$465K Buy
+174,967
New +$872K 0.23% 83

Other funds holding CNTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
DCM
Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Worth Venture Partners's CNTX Position: Q1 2023 in Review

Worth Venture Partners sold out of Context Therapeutics (CNTX) in Q1 2023, closing a stake of 281,889 shares — an estimated $186K sold.

Worth Venture Partners first reported a position in CNTX in Q4 2021 and held it in 5 quarters. The position peaked at $689K in Q1 2022. 22 funds tracked by Wall St. Rank hold CNTX as of Q1 2023.

  • Worth Venture Partners reported no remaining Context Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Worth Venture Partners sold 281,889 Context Therapeutics shares in Q1 2023, an estimated $186K.
  • Worth Venture Partners first reported a position in Context Therapeutics in Q4 2021 and held it in 5 quarters.
  • Worth Venture Partners's Context Therapeutics position peaked at $689K in Q1 2022.
  • 22 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2023.

Based on Worth Venture Partners's 13F filing for Q1 2023, filed 15 May 2023.